Immunic, Inc. (IMUX)
| Market Cap | 119.68M +38.3% |
| Revenue (ttm) | n/a |
| Net Income | -103.05M |
| EPS | -0.78 |
| Shares Out | 130.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,328,522 |
| Open | 0.9021 |
| Previous Close | 0.8983 |
| Day's Range | 0.8780 - 0.9380 |
| 52-Week Range | 0.5062 - 1.3500 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+445.08%) |
| Earnings Date | Feb 26, 2026 |
About IMUX
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patien... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for IMUX stock is "Strong Buy." The 12-month stock price target is $5.0, which is an increase of 445.08% from the latest price.
News
Immunic Announces Closing of Oversubscribed Private Placement Financing
– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiat...
Immunic Stock Jumps After Pricing $400 Million Private Placement
Immunic Inc (NASDAQ: IMUX) is surging Friday after the late‑stage biotech announced a private placement of up to $400 million.
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiat...
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity – – CALLIPER Subset Data Demonstrate Reductions in EBV-Specific T-Cell Re...
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 – – Phase 2 CALLIPER Data Showed Vidofludimus Calci...
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseas...
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
– Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presented at 41st Congress of ECTRIMS – – Phase 2 CALLIPER Data Demonstrated Statistically Significant 24-We...
Immunic to Participate in Industry and Investor Conferences in November
NEW YORK , Oct. 29, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...
Immunic to Participate in Scientific and Investor Conferences in October
NEW YORK , Oct. 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory...
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Over ...
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
– Fifth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis – – Comprehensive Intellectual Property Strategy Secures Protection Into 2041 in the U.S., Unless Extended Further – N...
Immunic to Participate in Investor and Scientific Conferences in September
NEW YORK , Sept. 4, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory...
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis Study Population and Across Subtypes, Reinforcin...
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW – – Vidofludimus Calcium Continues to Demonstrate Favorable Safe...
Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted
Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's s...
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in Pro...
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
NEW YORK , June 3, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi...
Immunic to Participate in Investor, Scientific and Industry Conferences in June
NEW YORK , June 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory...
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
NEW YORK , May 29, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi...
Immunic, Inc. Announces Proposed Public Offering
NEW YORK , May 28, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi...
Immunic to Participate in Scientific and Industry Conferences in May
NEW YORK , May 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Prim...
Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher
Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and rec...
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
NEW YORK , April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
NEW YORK , April 9, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therap...